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Fluorine-18 Fluorodeoxyglucose positron emission tomography-computed tomography (F-18 
FDG PET-CT) is now established in the staging, restaging and therapy response monitoring of 
Hodgkin’s lymphoma (HL) and high grade Non-Hodgkin’s lymphoma (HG NHL), specifically for 
nodal disease and extra-nodal disease excluding the bone marrow. 
The role of FDG PET-CT for evaluating bone marrow involvement in HL and HG NHL has not 
been established yet. There are however several publications on this subject but no consensus 
has been reached. 
Bone marrow trephine biopsy (BMB) is the gold standard for bone marrow assessment in 
lymphoma. Although the occurrence of adverse effects is uncommon, BMB is an invasive 
procedure that may induce anxiety in patients. 
A retrospective review of FDG PET-CT bone marrow findings of HL patients referred for a 
staging scan from June 2008 to January 2014 was done, these findings were compared to the 
BMB findings also done as part of initial staging. The findings of 55 patients were reviewed 
analyzed. 
There was concordance between the two modalities in 49 patients (89%), the other 6 patients 
(11%) showed discordance. Three were positive on BMB alone and the other 3 on FDG PET-CT 
alone. The agreement between the two procedures was good with a Kappa co-efficient of 0.63. 
vii 
 
In addition sensitivity, specificity, accuracy, positive predictive value (PPV) and negative 
predictive value (NPV) of FDG PET-CT bone marrow evaluation were calculated using BMB as a 
reference. These were found to be: sensitivity 70%, specificity 93%, accuracy 89%, PPV 70% and 
NPV 93%.  
In conclusion, the specificity and NPV were very good, implying that the absence of bone 
marrow involvement on FDG PET-CT done at initial staging for HL is a true reflection of absence 
of disease. A larger study is necessary to certainly consider omission of BMB in patients with no 
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Hodgkin’s lymphoma (HL) is a malignancy of lymphoid tissue, which may relatively rarely have 
extra-nodal involvement of the spleen, liver, lungs, bone marrow and other organs.1,2,3 It is 
common in the age groups 15 to 35 and 50 to 70.4,5 This malignancy is very responsive to 
treatment. The aim of therapy is cure.6 
Accurate staging at diagnosis is essential so that appropriate treatment is given. The detection 
of bone marrow involvement is important because it implies stage IV disease and necessitates 
the stratification to the most intense treatment group. Conversely identification of lack of bone 
marrow involvement is also essential in order to prevent over treatment that may result in 
chemotherapy induced organ toxicity.7,8 
The conventional method of staging HL includes clinical assessment; computed tomography of 
the neck, chest, abdomen and pelvis; and bone marrow trephine biopsy (BMB).3,7 Fluorine-18 
Fluoro deoxyglucose positron emission tomography- computed tomography (FDG PET-CT) has 
in the recent years emerged as a key tool in staging, restaging and treatment response of 
lymphoma, especially HL and high-grade non-Hodgkin’s lymphomas (NHL).9,10,11,12,13,14,15 
There is an abundance of literature on the role of FDG PET and PET-CT in lymphoma 
management; however its specific role in detection of bone marrow involvement has not been 
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established.9,10,11,12,13,14,15 Thus, BMB remains the method of choice for bone marrow 
involvement assessment in HL. 
The aim of this study is to evaluate the agreement between BMB findings and FDG PET-CT bone 
marrow activity in patients newly diagnosed with Hodgkin’s lymphoma.  
I have systematically reviewed the FDG PET-CT reports of patients with HL referred to the 
department of Nuclear Medicine at the Charlotte Maxeke Johannesburg Academic hospital and 
the Red Cross Children’s hospital Nuclear Medicine for a staging FDG PET-CT scan from June 
2008 to January 2014. The bone marrow findings on FDG PET-CT were correlated with the BMB 
findings, which were also done as part of initial staging of the patients. There was no treatment 





      Literature review  
 
 
Hodgkin’s lymphoma (HL) is a group of lymphoid neoplasms named after Thomas Hodgkin 
who first described abnormalities in the lymphoid glands and spleen in 1832.1 The disease 
accounts for less than one percent of all malignancies 16. There is a bimodal age incidence 
described, with peaks at ages 15 to 35 and 50 to 70 years; however, in economically 
disadvantaged countries the first peak is shifted towards childhood 4,5,17. There is a slightly 
higher male to female ratio incidence, in South Africa males show a 0.68/ 100 000/ year 
while females show a 0.49/ 100 000/ year incidence.16 
 
The aetiology of HL is unknown but several infections have been associated with it. Epstein-
Barr virus (EBV) infection has been shown to have a strong association with HL 
occurrence.18,19,20,21 Patients with Human immunodeficiency virus/ acquired immune 
deficiency syndrome (HIV/AIDS) are at an increased risk for developing HL.22 The increased 
risk has been associated with the introduction of highly active antiretroviral therapy 
(HAART) by some authors.23,24 Significant differences between HIV related HL and non-HIV 
related HL have been documented, such as: HIV-HL presents with high risk features like 
systemic B symptoms and extra-nodal involvement.22 Mononucleosis infection has also 
been implicated.25 Other predisposing factors are familial aggregation and genetic 
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susceptibility.26 Ferrais et al26 estimated that four and half percent of HL cases occur as 
familial HL. 
 
Hodgkin’s lymphoma usually presents as a localized disease subsequently spreading to 
contiguous lymphoid structures. Ultimately it disseminates to non-lymphoid tissues. 
Hodgkin’s lymphoma often presents with a newly detected mass or group of lymph nodes 
that are firm, freely movable and usually non-tender.27 About fifty percent of patients 
present with a mass in the neck or supraclavicular area and approximately sixty percent 
have a mediastinal mass at presentation27. Most children (ninety percent) present with 
painless adenopathy in the neck.27 The majority of patients with HL have few or no systemic 
symptoms related to the disease, however twenty five to thirty percent have constitutional 
symptoms (B symptoms), commonly low grade fever, night sweats and weight loss of 
greater than ten percent of body weight over a period of 6 months or less.27 Other 
symptoms include fatigue, malaise, weakness and pruritus.27 
 
The spread of HL is fairly predictable: nodal disease first, then splenic disease, hepatic 
disease, and finally marrow involvement and extra-lymphatic disease.28  
 
The Ann Arbor staging system with Cotswolds’ modification is currently used for clinical 





Stage Area of Involvement 
I Single lymph node group 
II Multiple lymph node groups on same side of diaphragm 
III Multiple lymph node groups on both sides of diaphragm 
IV Multiple extra nodal sites or lymph nodes and extra nodal disease 
X Bulky disease (maximal dimensions > 10 cm) 
E Extra nodal extension or single, isolated site of extra nodal disease 
A/B B symptoms: weight loss > 10%, fever, drenching night sweats. 
The diagnosis of HL requires an excision biopsy of the suspicious lymph node. The 
identification of Reed-Sternberg cells and their variants in a background of non-neoplastic 
inflammatory cells is essential for diagnosis.27,28 Immunohistochemical procedures are used 
to further classify HL as described by the WHO (world health organization) as two 
pathological disease entities: nodular lymphocyte predominant HL and classical HL. The 
latter has 4 subtypes: nodular sclerosing, mixed cellularity, lymphocyte rich and lymphocyte 
depleted HL.31 
 
Appropriate staging of HL is vital to determine the correct treatment and prognosis. The 
recommended staging procedures include: detailed history; physical examination; 
laboratory tests; chest X-ray; CT scans of the neck, thorax, abdomen and pelvis; and bone 




Bone marrow trephine biopsy in patients with HL is useful in clinical stages more than II A.33 
Stages II A and lower have been shown to have a less than one percent chance of bone 
marrow infiltration in adults and less than two percent in children.34,35,36,37 
Currently, a routine BMB is usually obtained from the iliac crest. Bone marrow trephine 
biopsy is an invasive diagnostic procedure, which allows analysis of a very limited area. 
Therefore unilateral or multifocal bone marrow infiltration at locations other than the iliac 
crest can consequently be missed.  
Pre-therapy FDG-PET-CT is strongly encouraged for HL because it can facilitate the 
interpretation of the post-therapy FDG PET-CT scan.9,10,11,12,13,14,15 The value of FDG-PET for  
detecting BM involvement however has not been sufficiently defined.  
 
Pakos et al38 performed a meta-analysis of 13 studies done before 2004, with a total of 587 
patients with HL and NHL, to evaluate the value of FDG-PET in bone marrow infiltration. 
They found that only about fifty percent of patients with bone marrow infiltration on BMB 
were detected as positive on FDG PET.38 However over ninety percent of the patients with 
negative BMB also had negative FDG PET scan for bone marrow infiltartion.38 On subgroup 
analysis they found that the sensitivity for bone marrow involvement on FDG PET is seventy 
six percent for HL and aggressive NHL. They concluded that FDG-PET may not replace but 





In a different study, Kabickova et al39 compared FDG PET with conventional staging methods 
(CT, sonar, BMB and bone scan) for children with HL and found a sensitivity of hundred 
percent on FDG-PET versus forty percent for BMB when looking at bone marrow 
infiltration.39  
 
Moulin-Romsee et al40 retrospectively analyzed 83 patients with HL and their ages were 
ranging from 7 to 82 years. They all had a BMB and FDG PET-CT at initial diagnosis.40 FDG 
PET-CT was negative for bone and BM in sixty of the eighty-three patients and all these 
patients also had a negative BMB. Eighteen of the eighty-three patients had positive FDG 
PET-CT bone and bone marrow findings; seven of which correlated with BMB findings. 
Eleven of the eighteen patients were negative on BMB. It is of note that in all the eleven 
discordant patients, the iliac crests were not involved on FDG PET-CT. FDG PET-CT bone/ 
bone marrow findings in five patients were reported as doubtful because they had strictly 
homogenous F-18 FDG uptake in the axial and proximal appendicular skeleton. None of 
these patients were treated as stage IV. In this series, FDG PET-CT depicted nine (10.7%) 
patients with bone/ bone marrow involvement that were missed by conventional staging 
(BMB and CT).40 
 
Six studies published between 2004 and 2010 with a total of 561 patients jointly showed 
forty-two patients with positive BMB; thirty-six of which were positive on FDG PET. Omitting 





Purz et al44 in another study compared the results of BMB and FDG-PET for the diagnosis of 
BM involvement in a large pediatric group of 175 patients with HL.44 They found that forty-
five patients were PET positive for BM involvement. Only seven out of one hundred and 
seventy five patients had positive BMB results and all seven were concordant with FDG PET 
bone marrow findings. All the detected lesions were verified either with the use of 
Magnetic Resonance Imaging (MRI) or CT or follow-up FDG-PET. There were no false 
negative PET lesions found. Therefore, the sensitivity and negative predictive value (NPV) of 
PET were hundred percent when using a combination of BMB, CT, or MRI results for 
reference. They concluded that FDG-PET has a high sensitivity and specificity, thus a routine 
BMB could be omitted.44  
      
Cheng et al45 did a retrospective review of paediatric patients (age range: 6-24 years) with 
HL and non-Hodgkin’s lymphoma (NHL) who underwent FDG PET-CT for staging at initial 
diagnosis. They included patients with pathological abnormal bone marrow on BMB, thirty-
one HL and twenty-three NHL (total: 54). In HL patients FDG PET-CT showed four out of 
thirty one patients to have positive bone marrow findings, all these sites resolved on follow-
up scans post therapy. Bone marrow trephine biopsy showed 2 positives of these 4 patients. 
The other two that were positive on FDG PET-CT showed abnormal bone marrow uptake in 
sites other than the iliac crests. Overall (HL and NHL) the sensitivity of FDG PET-CT was 





Muzahir et al46 retrospectively reviewed one hundred and twenty two patients with HL ages 
6 to 78 years. The sensitivity of FDG PET-CT was found to be a hundred percent; specificity 
seventy seven percent; NPV seventy seven percent; PPV thirty percent. They concluded that 
FDG PET-CT and BMB are complementary in the evaluation of bone marrow disease.46 
 
Cerci et al43 prospectively analyzed 82 patients with newly diagnosed HL. FDG PET detected 
all 16 patients who were characterized positive by BMB and identified an additional 4 
patients with bone marrow infiltration. They concluded that incorporation of FDG PET in the 
conventional staging procedures changed management in 15% of their patients.43 
 
Wu et al47 did a meta-analysis of 32 original articles (from 1995 to 2010) to evaluate the 
detection of bone marrow infiltration during staging and re-staging of lymphoma using FDG 
PET, FDG PET-CT and MRI. They found that FDG PET-CT had the highest sensitivity and 
specificity of the three modalities. Sensitivity: FDG PET-CT at 92%, FDG PET at 82%, MRI at 
90% and specificity: FDG PET-CT at 90%, FDG PET at 87%, MRI at 76%.47 
 
Recently Berthet et al48 retrospectively reviewed 133 patients with high-grade diffuse large 
B-cell lymphoma (DLBCL) who had an FDG PET-CT and BMB for initial staging. FDG PET-CT 
demonstrated bone marrow infiltration in 32 patients and only 8 patients by BMB. The 
reference was 24 months follow-up and targeted MRI imaging. Therefore the sensitivity, 
negative predictive value and accuracy for FDG PET-CT versus BMB were 94% vs 24%; 98% 
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vs 80%; 98% vs 81%, respectively. They concluded assessment of bone marrow infiltration 
with FDG PET-CT provides better diagnostic performance in newly diagnosed DLBCL than 
does BMB.48 
 
 Many authors now agree that FDG PET/ PET-CT improves sensitivity and specificity of bone 
and bone marrow involvement in patients with HL and high grade NHL.39,40,41,42,43,44,45,46,47,48 
Therefore the role of BMB as a gold standard for bone marrow involvement in these 































            Materials and methods 
 
 
      3.1 Study Design 
 
This is a retrospective study on patients with HL referred for a staging FDG PET-CT scan 
at the Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) Nuclear Medicine 
department. The referrals also included patients from the Chris Hani Baragwanath 
Academic hospital (CHBAH). To increase the study population, data from Red Cross 
Children’s hospital (RCCH) were also included.  
 
The archived FDG PET-CT and BMB histology reports (and FDG PET-CT images where 
available) of newly diagnosed HL patients were systematically reviewed and compared. 
FDG PET-CT images of patients with discordant (FDG PET-CT/ BMB) results were 
carefully reviewed to attempt to establish the reason for the discordance. The available 
clinical notes especially of the patients with the discordant findings were also reviewed. 
 
3.2 Inclusion and exclusion criteria 
The inclusion criteria are patients with newly diagnosed HL who had a pre-treatment 
FDG PET-CT scan and BMB as part of the initial staging. FDG PET-CT reports of seventy 
two patients were reviewed, seventeen of which were excluded for the following 
reasons: the BMB was not done as part of initial staging or the scan was actually done 
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after commencement of treatment or BMB specimen was suboptimal and one patient 
had a single equivocal BM finding on PET-CT even on review of the images.   
 
3.3 Study population 
A total of 55 patients were included in the study, 41 from the CMJAH-CHBAH complex 
and 14 from RCCH. This population consists of 43 males and 12 females; ages ranging 
from 3 to 32 years with a median age of 10 years. All the scans were done for 
diagnostic purposes in accordance with the international guidelines, European 
association of nuclear medicine guidelines.49 Images at the CMJAH and RCCH were 
acquired on the Siemens Biograph 40 PET-CT scanner (40 slice CT) and a Philips Gemini 
Big Bore PET-CT scanner (16 slice CT), respectively. Imaging was commenced sixty 
minutes on average following the intravenous administration of the radiotracer (F-18 
FDG). Some scans were contrast enhanced some were not, depending on the patient’s 
renal function or department protocol at the time. 
 
       3.4 Data management and analysis  
Patients’ FDG PET-CT reports were reviewed. The patients’ BMB results were sought for 
analysis. A comparison between the FDG PET-CT BM findings and BMB results was done 
for each patient. Descriptive analysis of the data was done to show the frequency 
distribution of variables. Concordance and discordance between the two modalities 
was documented. Bone marrow findings on FDG PET-CT were evaluated using visual 
assessment with liver uptake as a reference and the pattern of uptake (heterogenous 
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versus inhomogenous).  The maximum standardized uptake value (SUVmax) of the FDG 
accumulation in bone marrow/ bone was used as a semi-quantitative index. The 
agreement between the two modalities was measured using the Cohen Kappa co-
efficient. The sensitivity, specificity, accuracy, positive predictive value (PPV) and 
negative predictive value (NPV) of FDG PET-CT bone marrow evaluation were calculated 
using BMB as a standard of reference. Data were analyzed using Statistica 10 package 
(statsoft Inc, Tilsa, Oklahoma, USA). 
 
            3.5 Image interpretation 
 
FDG PET-CT bone marrow findings were considered positive when the uptake was 
above liver uptake and the pattern was heterogenous or focal.50,51,52,53 
 
3.6 Ethical issues 
Permission was obtained from the CMJAH chief executive officer (CEO), Wits ethics 
committee, University of Cape Town (UCT) paediatric research committee and faculty 
ethics committee, as well as the RCCH CEO. Confidentiality was maintained by assigning 

















A total of 55 patients with HL, whose initial staging included bone marrow biopsy and FDG PET-
CT were included. The characteristics of the population were 43 males and 12 females; ages 
ranging from 3 to 32 years with a median age of 10 years; Seventy five percent of patients were 
under the age of 13 years. The patient characteristics and findings are summarized and 
tabulated in tables 1 and 2, respectively. 
 
4.1 Concordance: negative BMB and negative FDG PET-CT bone marrow findings 
 
Forty-two out of fifty five patients were found to have negative BMB and negative FDG PET-CT 
bone marrow findings (76.4%).  
 
4.2 Concordance: positive BMB and positive FDG PET-CT bone marrow findings 
 
Seven out of fifty five patients were found to have positive BMB and positive FDG PET-CT bone 
marrow findings (12.7%). FDG PET-CT scan showed abnormal increased uptake in the pelvis 
(among other sites) in all seven patients, including iliac blade involvement specifically. Figure 1 
shows one of these patients, C28. 
 






4.3 Discordance: negative BMB and positive FDG PET-CT bone marrow findings 
 
Three out of fifty five patients (5.5%) had negative BMB and positive FDG PET-CT bone marrow 
findings. Two of these patients had bone marrow involvement in sites other than the pelvis: T8, 
L1 vertebrae and left femur in patient R36 (Figure 2); and L2 vertebra in patient R37 (Figure 3). 
Patient C30 had pelvic involvement (Figure 4). Table 3 lists the characteristics of these patients. 
 
4.4 Discordance: positive BMB and negative FDG PET-CT bone marrow findings 
 
Three out of fifty five patients (5.5%) had positive BMB and negative FDG PET-CT bone marrow 
findings. The BMB histology report described minimal infiltration (a single atypical cell) of bone 
marrow by metastatic HL in the one patient [patient R35 (Figure 5A)]. Another had 50% bone 
marrow involvement on BMB [patient C7 (Figure 5B)]. The third patient had extensive bone 
marrow infiltration by HL on BMB histology [patient R44 (Figure 5C)]. These patients’ 
characteristics are listed in table 4. 
 




The level of agreement was calculated using the Kappa co-efficient and it was found to be good 
at K 0.63, 95% CI [0.36 – 0.90]. 
 
4.6 Study sensitivity, specificity, PPV, NPV and accuracy 
 
Bone marrow biopsy is the gold standard for marrow evaluation is lymphoma, therefore in this 
study the sensitivity, specificity, PPV, NPV and accuracy of FDG PET-CT for bone marrow 
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infiltration are calculated with BMB as a reference standard: the sensitivity is 70% [0.70 +/- 
0.28] (42 to 98%); specificity is 93% [0.93+/- 0.07] (86 to 100%); PPV is 70% (42 to 98%); NPV is 








































Fluorine-18 Fluorodeoxyglucose positron emission tomography-computed tomography (F-18 
FDG PET-CT) is a technique which employs the use of a radioactive pharmaceutical F-18 FDG, 
which is an analogue of glucose. Since the metabolism of glucose is up-regulated in most 
malignancies, including HL, F-18 FDG is therefore an ideal imaging agent. Many studies have 
shown the usefulness of FDG PET-CT in staging, restaging and therapy monitoring of patients 
with lymphoma.9,10,11,12,13,14,15 In this study we compare FDG PET-CT performance in bone 
marrow infiltration evaluation in newly diagnosed HL against the current gold standard, BMB. 
 
Pakos et al38 in a meta-analysis of 13 studies done before 2004: 4 studies with HL, 3 studies 
with NHL patients and 6 mixed population; showed a sensitivity of 76% for the subgroup of HL 
and HG NHL in detecting bone marrow infiltration using FDG-PET and a specificity of 92%. These 
findings are similar to our study as we found a sensitivity of 70% and a specificity of 93% (86 to 
100%). Sensitivity was reasonable for HL (76%) but very few patients with HL had bone marrow 
infiltration, therefore they recommended that the sensitivity be verified by larger studies. This 
is also true for our study, few patients had bone marrow infiltration, seven were positive on 
both modalities, three on BMB alone and another three on FDG PET-CT alone; therefore overall 
thirteen positive studies out of fifty five, 23.6%. That is why the sensitivity is not that good at 




Kabickova et al39 did a prospective study on fifty-five children and adolescents with HL, 
comparing conventional methods (CT, sonar and BMB) with FDG PET for evaluating extra-nodal 
involvement at initial staging. They found that in six patients (10.9%) FDG PET revealed focal 
bone marrow infiltrates, all of which were negative on BMB. In fact a targeted MRI was used 
and confirmed these findings.39 In our study three out of fifty five patients (5.5%) had BM 
infiltration on FDG PET and were negative on BMB. The overall sensitivity of FDG PET for extra-
nodal involvement (including lungs, liver, spleen and BM) was 90% whereas the sensitivity for 
conventional methods was 80%.39 Their sensitivity is higher than ours (90 vs 70%) because all 
the other organs were included whereas we only looked at BM. 
 
Pelosi et al42, in a study of 194 patients in 2008, compared the usefulness of FDG PET versus 
BMB in patients with HL and aggressive NHL and its impact on therapy, they subsequently 
followed- up with a similar but multicenter population of 337 patients in 2011 using FDG PET-
CT.50 They initially found a sensitivity of 65.3%, specificity of 98.6% and NPV of 100%.42 In the 
multicenter study, the sensitivity was found to be 69%, specificity 99% and NPV of 90%.54 
The latter findings are similar to ours: sensitivity 70%, specificity 93% and NPV 93%; even 
though their population was mixed (HL and aggressive NHL).  
 
Purz et al44 evaluated bone marrow infiltration in a population of 175 children and adolescents 
with HL above stage II A. Forty five (25.7%) patients had BMI on FDG PET, only seven (4%) of 
which were also positive on BMB. They found a sensitivity and NPV of PET for BMI to be 100%, 
when a combination of CT, MRI and BMB were used as standard of reference.44  There were no 
false negative findings on FDG PET.44 This finding of a high NPV is similar to our study (93%) and 
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the other studies of Pelosi et al42,54 (100 and 90%). The high sensitivity is unlike any of the 
studies including our own. The possible reason might be because of a selected population of 
above stage IIA. Another study with a high sensitivity is by Cheng et al45, with a sensitivity of 
92%, their population however was mixed including HL, NHL, Burkitt’s lymphoma and T-cell 
lymphoma. Another study with a high sensitivity was Muzahir et al46 who retrospectively 
reviewed 122 patients, eighty-five of which had BM infiltration on FDG PET-CT and all of them 
were positive BMB, therefore the sensitivity was 100%.46  
 
In the previously mentioned multicenter study of Pelosi et al54, eighty-seven (26%) patients out 
of 337 had bone marrow infiltration. Twenty-five of these 87 patients (29%) had BM infiltration 
that was detected by both modalities. Twenty-seven of patients in this group (3%) were 
detected by BMB alone and 35 patients (40%) by PET-CT alone.54 In our study, a total of 
thirteen patients (24%) had positive bone marrow findings. Seven out of these thirteen patients 
(54%) were positive on both modalities, three (23%) on BMB alone and another three (23%) on 
PET-CT alone. Their highest pick-up rate was on PET-CT alone (40 %), whereas our highest pick-
up rate was noted when both modalities were combined (54%) [Figure1].  
 
Cerci et al43 studied 82 patients, 5 of which had bone marrow infiltration on PET that were not 
demonstrated by BMB. They proved 4 of the 5 patients to be true positives by MRI and bone 
scan and in all 4 patients the bone marrow uptake disappeared after therapy. Only 1 of the 5 
was regarded as a false positive because it corresponded to a rib fracture on the CT scan.43 This 
however would not be a concern in studies and institutions where integrated PET-CT is used, 
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like ours. Our findings are similar to Cerci et al, all three patients in our study had follow-up 
scans post therapy to assess response to treatment, which showed disappearance of abnormal 
bone marrow uptake, therefore they may be regarded as true positives. 
 
Moulin-Romsee et al40 had 11 out of 83 patients with BM infiltration on FDG PET-CT that were 
not detected on BMB.40  In a number of studies including Cerci and Moulin-Romsee et al43,40 
none of the FDG PET positive/ BMB negative patients had pelvic infiltration on the scan.40,43,45,46 
In our study, two of the three patients with BM infiltration on FDG PET-CT but negative BMB 
(patients: R36 and R37) did not show abnormal FDG activity in the pelvis. This may explain why 
the BMB findings were negative, since iliac crests are the standard sites of biopsy. In the 
remaining patient (C30) there was bilateral iliac blade involvement on FDG PET-CT. The 
discordance may be due to the inhomogenous pattern of infiltration. A sampling error might 
have occurred (a single core biopsy was obtained, but the side was not specified). Table 3 lists 
the characteristics of these 3 patients and figures 2, 3 and 4 show the sites and pattern of 
uptake. 
 
We had 45 patients without BM infiltration on PET-CT and 42 of them were also negative on 
BMB. Therefore three were discordant with BM infiltration on BMB which was not detected by 
FDG PET-CT, these are patients C7, R35 and R44 (table 4 and Figure 5). The extent of BM 
infiltration on BMB ranged from a single lesion to 50% infiltration to extensive infiltration. The 
extent of infiltration does not seem to be the contributory factor for the lack of detection by 
the FDG PET-CT. The only notable common characteristic between these patients was the 
atypical clinical presentation that is none of them had significant cervical, supraclavicular or 
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axillary adenopathy. The diagnosis of HL was made on BMB, thoracotomy and laparotomy. The 
significance of this fact is however unclear. 
 
 
5.1 Study Limitations 
 
It is a retrospective study. 
This is a small sample size due to the relative newness of the FDG PET-CT imaging modality 
(about 5 years at CMJAH), thus it is not formally integrated into the staging algorithms of most 





























Conclusion and way forward 
 
 
This study has demonstrated the performance of FDG PET-CT in evaluating bone marrow in 
patients with HL who are referred for initial staging. We measured the agreement between FDG 
PET-CT bone marrow uptake and BMB findings in this group of patients. The vast majority of 
patients without bone marrow infiltration on FDG PET-CT also did not show involvement on 
BMB, therefore the specificity and NPV were high at 93%. These findings suggest that BMB may 
not be necessary at initial staging in patients with HL who will have a FDG PET-CT scan as part of 
























Table 1: Summary of patient characteristics 
Total number of patients 55 
Males (M) 43 
Females (F) 12 
Age range  3 – 32 years 
Age median 10 years 
Age 1st quartile 6 years 
Age 2nd quartile 13 years 






























M   Male 
 F  Female 
CS  Clinical stage 
LNs  Lymph nodes 
 BM  Bone marrow 
 BMI  Bone marrow infiltration 
 PMR  Partial metabolic response 
PLT  Platelets 
P.T.B.  Pulmonary Tuberculosis 
T.B.  Tuberculosis  
RVD  Retroviral disease 
Rx  Treatment 
              HAART  Highly active retroviral therapy 
C-X ray  Chest X-ray 
CT  Computed Tomography 
MRI  Magnetic resonance imaging 








Gender BMB         FDG PET-CT Comparison Time interval 
(days) 
Stage on PET-CT and 
BMB  SUVmax 
C1 23 M Negative Negative - Concordant  114 IV (subcut. nodules) 
C2 4 F Negative Negative - Concordant 6 III 
C3 12 M Negative Negative - Concordant 5 IIE (lungs) 
C4 10 M Negative Negative - Concordant 7 II 
C5 18 F Positive Positive  7.42 Concordant  126 IV (liver and BM) 
C6 10 F Negative Negative - Concordant 265 (defaulted) IV (lungs) 
C7 11 M Positive Negative - Discordant 13 III 
C8 7 M Negative Negative - Concordant 11 II 
C9 6 M Positive Positive 5.24 Concordant  18 IVS (BM) 
C10 16 M Negative Negative - Concordant 9 II 
C11 8 M Negative Negative - Concordant 28 IIIS 
C12 10 M Negative Negative - Concordant  1 IIIS 
C13 8 M Negative Negative - Concordant  0 II 
C14 14 F Positive Positive  ? Concordant 8 IV (BM) 
C15 18 F Negative Negative - Concordant 62 II 
C16 11 M Negative Negative  - Concordant 92 III 
C17 13 M Negative Negative - Concordant 9 II 
C18 12 M Negative Negative - Concordant 16 II 
C19 9 M Negative Negative - Concordant 19 IIIS 
C20 11 M Negative Negative - Concordant 3 IIIS 
C21 5 F Negative Negative - Concordant 16 III 
C22 7 F Negative Negative - Concordant 5 II 
C23 32 F Negative Negative - Concordant 26 II 
C24 4 M Negative Negative - Concordant 14 III 
C25 10 M Negative Negative - Concordant 20 IV (liver and lungs) 
C26 5 M Negative Negative - Concordant 10 II 
C27 17 F Negative Negative - Concordant 10 II 
C28 4 M Positive Positive 6.14 Concordant 1 IV (BM) 
C29 29 M Positive Positive 5.66 Concordant 29 IV (BM) 
C30 27 F Negative Positive 5.19 Discordant 1 IV (BM) 
C31 11 M Negative Negative  - Concordant 7 II 
C32 4 M Negative Negative - Concordant 10 I 
R33 9 M Negative Negative - Concordant 4 I 
R34 5 M Negative Negative - Concordant 2 I 
R35 7 M Positive Negative  - Discordant 3 II 
R36 14 M Negative Positive 7.99 Discordant 11 IV (BM) 
R37 7 M Negative Positive 3.96 Discordant 4 IV (BM) 
R38 9 M Negative  Negative - Concordant  4 II 
R39 6 M Negative  Negative - Concordant  1 II 
R40 13 F Negative  Negative - Concordant  2 II 
R41 4 M Negative  Negative - Concordant  4 II 
R42 3 M Negative  Negative - Concordant  1 II 
R43 12 M Positive Positive 13.32 Concordant  1 IV (BM) 
R44 6 M Positive Negative - Discordant  15 III 
R45 13 M Negative  Negative - Concordant  4 II 
R46 5 M Negative  Negative - Concordant 5 I 
C47 5 M Negative Negative - Concordant 0 II 
C48 7 M Negative Negative - Concordant 6 II 
C49 8 M Negative Negative - Concordant 10 II 
C50 30 F Negative Negative - Concordant  24 IIIS 
C51 7 M Negative Negative - Concordant 5 II 
C52 22 M Negative Negative - Concordant 2 IIE (lungs) 
C53 5 M Negative Negative - Concordant 21 IIIS 
C54 13 M Negative Negative - Concordant 1 IE (liver) 
C55 12 M Positive  Positive  4.57 Concordant 10 IV (BM) 






Table 3: Characteristics of FDG PET-CT positive and BMB negative patients 
No. Patient ID Age 
(yrs) 
Gender  Subtype of HL Clinical stage and 
presentation 
BMB FDG PET-CT Follow-up PET-
CT Post 
therapy 
1 C30 27 F Not specified CS: Stage IIIA. 
Neck mass.  
Splenomegaly. 
Negative  Positive  
Stage IV  
BMI: multiple 




Residual in the 
LNs. 
 BM clear. 
2 R36 14 M Nodular 
sclerosing 






Negative  Positive  
Stage IV  












Negative  Positive  
Stage IV  
BMI:L2. 
PMR: 
































Gender  Subtype of 
HL 














believed to be 
drug induced 
hepatitis. 
PTB on Rx, 3rd 
course. 





















































R44 6 M Nodular 
Sclerosing 
No improvement 


















































A                                B  
 
Figure 1: Patient C28, extensive bone marrow infiltration throughout the skeleton with CT bone 
changes in the right femur. Bone marrow infiltration was also found on BMB. A, coronal FDG 




















Figure 2: Patient R36. There is bone marrow infiltration in T8 and left femur, the pelvis was not 




















Figure 3: Patient R37, showing bone marrow infiltration in L2 vertebral body. There was no 














Figure 4: Patient C30 showing BM infiltration on FDG PET-CT in the thoraco-lumbar spine and 

























B                C  
Figure 5: Patients C7, R35 and R44; A, B and C, respectively show no evidence of bone marrow 
infiltration on FDG PET-CT but BMB was positive of HL. Histology reported: A. C7 a 50% 
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